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Summary
AIMS OF THE STUDY: Skin cancer is a burden to health-
care and patients worldwide. The incidence of skin cancer
has been rising during recent decades and this trend is
expected to continue in the future. Numerous risk factors
have been identified and prevention strategies developed.
The Euromelanoma campaign is a pan-European skin
cancer prevention programme, targeted to both primary
and secondary prevention of malignant melanoma. The
current study aimed to evaluate the results of the Swiss
skin cancer screening day 2016.
METHODS: A questionnaire was used to obtain data on
characteristics and suspected skin cancers of all partici-
pants. Follow-up of patients with suspicious lesions was
performed 3 to 6 months later.
RESULTS: During the campaign, 2795 people were
screened. Of the screened individuals, 157 participants
(58% female, 42% male; mean age 58.8 years) underwent
further evaluations; 6 cutaneous malignant melanomas,
21 basal cell carcinomas and 2 squamous cell carcinomas
were detected. Detection rates were 0.21% for cutaneous
melanoma, 0.75% for basal cell carcinoma and 0.07% for
squamous cell carcinoma.
CONCLUSIONS: Our study provides an up-to-date eval-
uation of the Swiss Euromelanoma campaign 2016. The
results are mostly in line with data from other European
studies. Considering the morbidity, mortality and financial
and social impact of skin cancer, the capacity to raise
awareness of risk factors, skin cancer prevention methods
and educating high-risk and at-risk individuals, we may as-
sume that a National Screening Day has a crucial impact
on the public health system.
Key words: Euromelanoma, malignant melanoma, na-
tional campaign, screening, skin cancer
Introduction
Skin cancer is a non-negligible burden to healthcare and
patients alike. Epidemiological data are collected on a reg-
ular basis to estimate the extent of the disease. Various
prevention approaches have been introduced to reduce the
burden of skin cancers. Primary prevention focuses on
spread of information about and reduction of skin cancer-
related risk factors and behaviour, namely reducing sun
exposure, avoidance of sunburn and artificial tanning or
use of sunscreen when ultraviolet radiation (UV) exposure
is unavoidable. Furthermore, it tries to raise awareness
among the public of warning signs of skin cancer [1–3].
Secondary prevention aims to diagnose and treat skin can-
cer at a potentially curable stage, to improve prognosis
and thus reduce the burden of melanoma on healthcare re-
sources and patients [1, 2].
Euromelanoma is a pan-European campaign for skin can-
cer prevention, which was initiated in 1999 and has now
spread to 29 European countries. This campaign is targeted
to both primary and secondary prevention of malignant
melanoma (MM) and nonmelanoma skin cancers (NM-
SCs) by increasing the public awareness of skin tumours
via media campaigns and by providing free skin examina-
tions to the general public once a year, at the end of May
before the summer holiday season [1–4].
As Switzerland has one of the highest incidences of cuta-
neous melanoma in Europe [5, 6], a National Skin Cancer-
Screening Day has been organised there since 2001, on a
yearly base [5, 7]. In 2006, the Swiss Society for Derma-
tology and Venerology (SSDV), in collaboration with the
Swiss Cancer League, shifted its skin cancer prevention
activities towards a Euromelanoma Screening Week Cam-
paign to promote primary prevention measures by use of
media advertising to a large public and the direct education
of the patient at the screening day itself [5, 7]. The cur-
rent study aimed to evaluate the results from the Swiss skin
cancer screening day 2016 and investigate the number of
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skin cancer diagnoses based on the suspicious lesions de-
tected.
Material and methods
A free-of-charge skin examination was offered within the
annual Euromelanoma skin cancer prevention campaign
and organised by the SSDV (from 30 May 2016 to 3 June
2016). In the National Skin Cancer Campaign 2016, 93
medical centres (69 dermatological practices and 24 gener-
al practices) were involved. Participating physicians (der-
matologists and general practitioners) in hospitals or in
private practices conducted the screening examinations.
Participating doctors chose whether they wanted to see pa-
tients by appointment or if people could turn up at their
practice freely.
The examination process was structured by using the stan-
dardised European questionnaire developed in 2008 [7, 8]
(see appendix 1). The questionnaire consists of three sec-
tions:
1. General information. This part was filled out by the
person screened. This section contained questions
(multiple answers were possible for some of the ques-
tions) about personal data: age, gender, motivation for
participation and prior skin examination. Questions re-
garding main skin cancer risk factors (skin colour and
photo type, sunburn before the age of eighteen, va-
cation in countries with high ambient solar radiation,
occupational sun exposure) and preventive behaviour
e.g. use of sunscreen during short sun exposure or sun-
baths were included. Levels of education were not as-
sessed because of the bad accordance of the European
standardised questionnaire with the Swiss education
system.
2. Clinical information. This part was completed by
physicians after taking a family history and previous
skin cancer history, followed by a skin examination,
dermatoscopy, and recorded findings and suspected di-
agnosis. The clinical inspection consisted of identi-
fying the number of nevi, existence of atypical nevi,
actinic keratosis and suspicious lesions (malignant
melanoma, basal cell carcinoma, skin squamous cell
carcinoma, other).
3. Management decision. In a final step, one of the fol-
lowing recommendations was made by the physicians:
No further action required
Check-up visit, excision by dermatologist and treat-
ment suggested
Biopsy recommended
Patients were informed about the aim of the study (for
quality assessment) and study procedures, and could leave
their e-mail address or phone number when they agreed to
participate. Ethics approval was not necessary according
to Swiss Human Research Act (https://www.admin.ch/opc/
en/classified-compilation/20061313/index.html, accessed
April 8, 2016). All questionnaires were sent to the SSDV
office. After 3 to 6 months, all screened persons partici-
pating in the study who had a suspicious lesion were con-
tacted either by e-mail or telephone. In the case of no-
response, the patient was contacted for a second time.
Patients who gave their permission were asked whether
they had followed the physician’s recommendation. Final-
ly, the patients were asked about the definite diagnosis. All
results of the questionnaire and the follow-up data were
collected in a file.
Statistical analysis
For descriptive purposes, data were presented as means
with standard deviations (SDs) or numbers with percent-
ages for continuous and categorical variables respectively.
Prevalences (i.e., detection rates) of selected skin cancers
and other precancerous conditions within the study sample
were presented along with their exact (Clopper-Pearson)
95% confidence intervals (CIs). The ratios between study
prevalences and known estimates from the general Swiss
population (i.e., prevalence ratios), where available, were
computed, with exact 95% CIs and p-values. Detection rate
is defined here as the percentage of subjects in the overall
study population who had a positive diagnosis of skin can-
cer or other precancerous conditions after clinical assess-
ment.
All tests were considered statistically significant at p-value
<0.05. The analysis was carried out using Matlab software,
ver. 7.8 (The MathWorks Inc., Natick, MA, USA).
Results
The participating physicians examined 2795 individuals
(Female: 63.2%, Male: 36.8%) with mean (SD) age of
51.65 (18.25) years, covering all of Switzerland’s geo-
graphic regions. Figure 1 presents the entire workflow.
A total 2215 (79.3%) screened individuals required no
further treatment. Suspicious lesions were found in 580
(20.7%) patients. Out of these 580 patients, 243 (41.9%)
patients did not agree to be contacted again to assess qual-
ity 3 to 6 months later. From the 337 who were willing to
participate in the study, 140 (41.5%) were not reachable
because of either incorrect contact details or no reply. Of
the 197 available patients, 40 (20.3%) patients declared not
having followed the physician’s recommendation of refer-
ral to a dermatologist. The remaining 157 (79.7%) partici-
pants had a check-up visit at a dermatologist.
A total of 81 out of 157 lesions were reported to be biop-
sied. Among these 157 cases were found 6 MM (6/6 biop-
sied), 21 basal cell carcinomas (BCCs) (17/21 biopsied),
2 squamous cell carcinomas (SCCs) (2/2 biopsied), 44 ac-
tinic keratoses (8/44 biopsied) and 3 dysplastic/atypical
naevi (3/3 biopsied). Seventy-four cases were without
pathological findings (41/74 biopsied) and in 7 cases the
diagnosis was not communicated. Detection rates differed
between the various types of skin cancer. The malignant
melanoma detection rate was 1:466 and the detection rate
for BCC was 1:133. SCC detection rate was the lowest at
1:1398. (table 1)
Demographics
The description of the epidemiological data is based on the
157 (91 female, 66 male) participants with a suspicious
lesion who underwent a referral to a dermatologist. The
majority of the 157 patients were female (58.0%) and the
mean age was 58.8 years for both genders. The skin photo-
types I, II, III or IV were reported for 8.9%, 15.9%, 47.1%
and 23.6% of the patients, respectively. Overall, 69.4% had
never had a skin cancer screening before. Most of the par-
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ticipants (47.8%) attended the screening for a general skin
examination; 40.1% gave a high number of naevi as a rea-
son to participate in the campaign and about one fifth of the
patients (21.7%) were concerned about a specific or newly
appeared lesion. (table 2)
Risk factors
Table 3 shows the distribution of sun-related risk factors
and history of skin cancer. Most patients showed neither
a positive family history (88.5%) nor a personal history
(91.7%) of skin cancer; 46.5% had fewer than 25 naevi
and a minority of 5.7% presented more than 100 naevi. Re-
garding sun-seeking behaviour, 41.4% of the participants
confirmed a sunburn under the age of 18 years (38.2%
had no sunburn). Sunscreen was reported to always be
applied when sunbathing by 59.9%, 21.7% of the partic-
ipants sometimes used sun protection and 13.4% never
sunbathed. Reportedly, 23.6% never went on vacation to
highly sun-exposed areas, 45.9% stayed in such regions for
up to 2 weeks and 28.7% more than 2 weeks per year.
Prevalence
Prevalence estimates of skin cancers and other precancer-
ous conditions, in detail, and comparisons with known es-
timates from the general population are reported in table
4. Overall. 6 patients in the sampling population had a
diagnosis of MM with an estimated prevalence of 21.5
× 10 000 (95% CI 7.9–46.7). Regarding NMSC, the ob-
served prevalence of BCC was 75.1 × 10 000 (95% CI
46.6–114.6), and the prevalence of SCC was 10.7 × 10 000
(95% CI 2.2–31.3). For other precancerous conditions, the
estimated prevalence of actinic keratosis in our sample was
157.4 × 10 000 (95% CI 114.6–210.8, and the prevalence
of dysplastic naevus was 10.7 × 10 000 (95% CI 2.2–31.3).
Discussion
Skin cancer is one of the most common cancers in Switzer-
land [11]. In this study, data collected during the Swiss Eu-
romelanoma screening day 2016 were analysed to provide
a current picture of the impact of the campaign and a basis
for future measures to improve the screening event.
The detection rates of melanoma in Euromelanoma pro-
grammes varied substantially across participating coun-
tries (from 0.1 to 1.9%) [3]. The results of the 2016 Swiss
Euromelanoma Day showed a detection rate for melanoma
of 0.21%, which is compatible to similar European and
American studies [1–3, 12, 13]. However, compared with
the Swiss Euromelanoma evaluation conducted in 2008
with the same methodology and public awareness strategy
on 1312 screened individuals [7], the melanoma detection
rate was found to be lower (0.21 vs 0.30%).
Although the main focus of the Euromelanoma Day is the
early diagnosis of melanoma [14], our campaign also de-
tected some patients with NMSC; the BCC detection rate
was higher and SCC detection rate lower in 2016 com-
pared with 2008(0.75 vs 0.38% and 0.07 vs 0.15%, re-
spectively) [7]. Furthermore, comparisons of prevalence
estimates of skin cancers and other precancerous condi-
tions between the current study and the general population
showed that 6 patients in the sampling population had a
diagnosis of MM with an estimated prevalence of 21.5 ×
10 000. The observed prevalence was significantly high-
er than in the general population (prevalence ratio 6.4;
p <0.001). Regarding NMSC, the observed prevalence of
BCC was 75.1 × 10 000, and the prevalence of SCC was
Table 1: Distribution of diagnosis, biopsies and detection rate during Swiss Euromelanoma 2016†.
Diagnosis No. of reported cases No. of biopsies Detection rate*‡
n % %
MM 6 3.8 6 0.21
BCC 21 13.4 17 0.75
SCC 2 1.3 2 0.07
AK 44 28.0 8 1.57
Atypical naevus, Dysplastic nae-
vus
3 1.9 3 0.11
Not specified 7 4.5 4 0.25
Negative 74 47.1 41 2.65
AK = actinic keratosis; BCC = basal cell carcinoma; MM = malignant melanoma; NMSC = non-melanoma skin cancer; SCC = squamous cell carcinoma † based on recorded data
of 157 patients * Detection rate can be defined here as the percentage of subjects in the overall study population who had a positive diagnosis of skin cancer or other precancer-
ous conditions after clinical assessment. ‡ Detection rates of MM, SCC and BCC in the Swiss National Skin Cancer Campaign in 2008 were 0.3, 0.15 and 0.38%, respectively.
Table 2: Reasons for participation in the campaign and previous skin cancer screenings†.
No. of participants
n %
Reason for participation‡
Many naevi 63 40.1%
New or change in naevi 34 21.7%
Personal history of skin cancer 15 9.6%
Family history of skin cancer 14 8.9%
General skin examination 75 47.8%
Previous skin examination
Yes 46 29.3%
No 109 69.4%
Not specified 2 1.3%
† Based on recorded data of 157 patients ‡ Multiple answers allowed
Original article Swiss Med Wkly. 2017;147:w14511
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 3 of 7
10.7 × 10 000. Compared with general population esti-
mates, the prevalence of BCC was significantly higher
(prevalence ratio 9.4; p <0.001) [9]. For other precancer-
ous conditions, the estimated prevalence of actinic kerato-
sis in our sample was 157.4 × 10 000, similarly to previous
estimates from another study [10], while the prevalence of
dysplastic naevus was 10.7 × 10 000.
In 2016, 70.7% of the persons screened had a skin pho-
totype III or higher, which was similar to data reported
by individual Euromelanoma countries in previous years
[3]. Additionally, in concordance with Euromelanoma Day
campaigns in other countries, women were more likely
than men to participate in the Swiss screenings [3, 14].
Women are probably more conscious about the risk factors
and more accustomed to attending cancer screening cam-
paigns [14]. Sun exposure is a known risk factor of skin
cancers. Three quarters of all participants go on vacation
to destinations with high solar radiation on a yearly basis.
This behaviour results in elevated intermittent sun expo-
sure. Awareness of the need for adequate sun protection
while sunbathing seems to be high. The impact of unin-
tended sun exposure appears to be taken less seriously,
however. Twenty percent fewer screened persons used sun
screen when exposed to sunlight for one hour than sun-
bathers. The elevated numbers of BCCs and MMs could be
explained by widespread intermittent sun exposure. These
findings reveal a continuing need of public education about
UV radiation as a risk factor, not only when sunbathing but
also when exposure is not intended.
Skin cancer screening of an unselected population is con-
troversial: the Cancer Council Australia does not recom-
mend routine skin screening for average-risk individuals,
whereas the American Cancer Society supports this type
of regular screening [15]. Skin cancer screening could be
accompanied by psychosocial harms, cosmetic harms, or
overdiagnosis [16]. However, it was shown that skin can-
cer screening might be able to reduce disease-specific mor-
tality [17–22].
The success of the Euromelanoma days depends on many
factors, including the number of dermatologists who par-
ticipate, as well as the costs of the screening and infor-
mation campaigns. Furthermore, the characteristics of the
Table 3: Distribution of the risk factors family history of skin cancer, sunburn in childhood, use of sunscreen and vacation in areas with high sun exposure†.
No. of participantsRisk factors†‡
n %
Family history of skin cancer
Yes 12 7.6%
No 139 88.5%
Personal history of skin cancer
MM 6 3.8%
NMSC 6 3.8%
No 144 91.7%
Sunburn in childhood
Yes 65 41.4%
No 60 38.2%
Use of sunscreen during 1-hour exposure
Never 13 8.3%
Sometimes 76 48.4%
Always 66 42.0%
Use of sunscreen while sunbathing
Never 6 3.8%
Sometimes 34 21.7%
Always 94 59.9%
Vacation in sun exposed areas
Never 37 23.6%
Up to 2 weeks per year 72 45.9%
More than 2 weeks per year 45 28.7%
MM = malignant melanoma; NMSC = nonmelanoma skin cancer
† Based on recorded data of 157 patients
‡ Numbers do not always add up to the total because of missing data.
Table 4: Prevalence estimates of skin cancers and other pre-cancerous conditions, in detail, and comparisons with known estimates from the general population†.
Total
(n = 77)
Pr × 10 000 in the overall study pop-
ulation
(n = 2795)
(95% CI)
Pr × 10 000 in the general
population
Pr ratio#
(95% CI)
p-value
n %
BCC 21 13.4% 75.1 (46.6–114.6) 8.0* 9.4 (5.8–14.3) <0.001
SCC 2 1.3% 10.7 (2.2–31.3) 3.0* 3.6 (0.7–10.4) 0.06
MM 6 3.8% 21.5 (7.9–46.7) 3.3‡ 6.4 (2.4–14.0) <0.001
AK 44 28.0% 157.4 (114.6–210.8) 140 (120–180)§ 1.1 (0.8–1.6) 0.53
Dysplastic naevus 3 1.9% 10.7 (2.2–31.3) NA – –
AK = actinic keratosis; BCC = basal cell carcinoma; CI = confidence interval; MM = malignant melanoma; NA = not available; Pr = prevalence; SCC = squamous cell carcinoma †
Based on recorded data of 157 patients * Levi F et al. 2001 [9] ‡ 2012 EUCAN 1-yr Pr estimates for Switzerland § Naldi L et al. 2006 [10] # Prevalence: the relative frequency of
a condition of interest in the sampled population
Original article Swiss Med Wkly. 2017;147:w14511
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 4 of 7
Figure 1: Follow-up of participants Swiss Euromelanoma 2016.
population screened during Euromelanoma were influ-
enced by the message broadcasted and local rules of par-
ticipation [3].
Our current study was certainly not without limitations, be-
cause the individuals screened were relatively older than
the Swiss population, with a predominance of women. An-
other possible limitation of the study is that not all of the
subjects with suspect lesions were followed up, because
they did not give permission to be contacted for further
evaluation. This might have lowered our detection rate es-
timates. Nevertheless, the observed rates are significantly
higher, at least for MM and BCC, than the reference gener-
al population, showing a positive impact of a national cam-
paign of screening on detection rates.
All in all, skin cancer prevention initiatives are highly cost-
effective and may also be cost-saving [23]. Although the
direct benefits of skin cancer screening may be greatest
among subgroups most likely to develop fatal melanoma
[16], indirect consequences of screening campaigns should
not be underestimated. The impact of skin cancer diag-
noses on the awareness of the social circle of a patient
can hardly be measured. This spread of consciousness of
skin cancer might influence the risk factor-related behav-
iour and secondary prevention can thus reinforce primary
prevention efforts. Therefore, considering the morbidity,
mortality and financial and social impact of skin cancer,
the capacity to raise awareness of risk factors, skin cancer
prevention methods and educating high-risk and at-risk in-
dividuals, we may assume that a National Screening Day
does have a crucial impact on the public health system.
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Appendix 1 Questionnaires
The questionnaires are available as separate files for down-
loading at https://smw.ch/en/article/doi/smw.2017.14511/.
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